Every year, *Clostridioides difficile* — better known as C. diff — kills tens of thousands of people in wealthy countries alone. In the United States, it causes around 500,000 infections and 30,000 deaths annually. In the UK, it remains one of the most feared hospital-acquired infections.
What makes C. diff so dangerous is not just what it does — severe gut inflammation, profuse diarrhoea, potentially fatal colitis — but how it comes back. Even after successful treatment, approximately **20–30% of patients** experience a recurrence within weeks. In some cases, the cycle of infection, treatment, and relapse becomes a medical nightmare that can continue for months.
The reason is devilishly simple: the antibiotics used to kill C. diff also kill the beneficial gut bacteria that protect against it. With the microbiome wiped out, C. diff spores that survived the antibiotic onslaught find an undefended environment — and the infection returns.
A new antibiotic, developed by scientists at Leiden University in the Netherlands, may have found a way around this.
**What Is EVG7?**
**EVG7** is an experimental glycopeptide antibiotic — a more potent derivative of vancomycin, currently one of the main drugs used to treat C. diff. It was developed by Professor Nathaniel Martin's team at the Institute of Biology Leiden, and the key findings were published in *Nature Communications* in October 2025, with new coverage from ScienceDaily emerging in March 2026.
**The Breakthrough Results**
In mouse studies infected with C. diff, EVG7 delivered results that exceeded expectations:
✅ **High efficacy at extremely low doses** — EVG7 cleared C. diff infections at doses significantly lower than vancomycin, reducing the therapeutic threshold and, critically, the collateral damage to the gut.
🌿 **Microbiome preservation** — Unlike vancomycin, which decimates the gut flora, low-dose EVG7 treatment left beneficial *Lachnospiraceae* bacteria — one of the key families that naturally compete with C. diff — largely intact. With these protective bacteria surviving treatment, the conditions for relapse were dramatically reduced.
🔄 **Dramatically reduced recurrence** — Mice treated with low-dose EVG7 showed far lower rates of C. diff recurrence than those treated with conventional antibiotics. The microbiome that survived treatment continued to act as a living shield against re-infection.
🛡️ **No resistance promotion** — Even at low doses, EVG7 eradicated the infection without triggering antibiotic resistance — a critical consideration given the global threat of drug-resistant bacteria.
**Why This Problem Is So Hard**
The fundamental difficulty with treating C. diff is that it lives in the gut — the same environment as the beneficial bacteria the body depends on. Any antibiotic powerful enough to kill C. diff is, by definition, also killing beneficial flora. Vancomycin and metronidazole — the current first-line treatments — are effective, but they leave patients vulnerable to relapse precisely because of the collateral damage they cause.
EVG7's key innovation appears to be a combination of higher potency at lower doses *and* a selectivity that spares the protective members of the gut community. By preserving *Lachnospiraceae* specifically — bacteria that naturally suppress C. diff — the antibiotic essentially maintains the gut's own defence mechanism throughout treatment.
**What Comes Next**
EVG7 remains in the pre-clinical stage. Before human trials can begin, toxicity assessments are required — and Professor Martin's team is actively seeking funding to advance the research.
This is, unfortunately, a familiar bottleneck in antibiotic development. Unlike drugs for chronic conditions that patients take for years or decades, antibiotics are taken for short courses — which makes them less commercially attractive to large pharmaceutical investors. The researchers have been candid about the challenge.
But the scientific case is compelling. A drug that: - Is more effective than the current standard of care - Reduces recurrence by protecting the microbiome - Carries no resistance promotion at therapeutic doses
...would represent a step change in one of medicine's most persistent and lethal infection-control problems.
For the hundreds of thousands of C. diff patients worldwide who face the misery of relapse, EVG7 represents exactly the kind of targeted, elegant solution medicine has been searching for. 🔬💊
*Sources: ScienceDaily (March 11, 2026) · Nature Communications (October 2025) · Leiden University · SciTechDaily · Healthquill*
